<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Avian influenza vaccines</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Avian influenza vaccines</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Avian influenza vaccines</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Iain Stephenson, MD, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Avian influenza viruses are important viruses of pandemic potential. Outbreaks of avian influenza viruses among poultry and wild bird populations have prompted increased interest in pandemic preparedness. </p><p>Issues related to avian influenza vaccines for human use will be reviewed here. </p><p>Issues related to the epidemiology, transmission, pathogenesis, clinical manifestations, diagnosis, and treatment of avian influenza are discussed separately. (See  <a class="medical medical_review" href="/d/html/7002.html" rel="external">"Avian influenza: Epidemiology and transmission"</a> and  <a class="medical medical_review" href="/d/html/7001.html" rel="external">"Avian influenza: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/138869.html" rel="external">"Avian influenza: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H1184713426"><span class="h1">AUTHORIZED VACCINES</span><span class="headingEndMark"> — </span>Pandemic-specific vaccines must be distinguished from prepandemic vaccines: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pandemic-specific </strong>vaccines are developed only once a pandemic has been declared and the culprit virus has been characterized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To reduce delay, <strong>prepandemic</strong> vaccines are developed and authorized for use (but not marketed) prior to declaration of a pandemic [<a href="#rid1">1</a>]. In the event of a pandemic, the manufacturer can include the emerging virus subtype in the previously authorized vaccine then apply for final authorization. Ideally, this would facilitate expedition of the approval process since the safety and efficacy of the vaccine have already been assessed. </p><p></p><p class="bulletIndent1">There are several prepandemic vaccines authorized for human use in the United States and European Union that could be modified into pandemic-specific vaccines if a pandemic is declared. These are summarized in the table (<a class="graphic graphic_table graphicRef141146" href="/d/graphic/141146.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H3416878800"><span class="h1">HUMAN VACCINE DEVELOPMENT</span></p><p class="headingAnchor" id="H1023370690"><span class="h2">Challenges and novel approaches</span><span class="headingEndMark"> — </span>There have been multiple challenges to the development of avian influenza vaccines; these include:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic evolution (with several antigenically diverse virus clades and subclades) poses difficulty in selecting the best viruses from which to prepare vaccines. This challenge could be mitigated by the development of a universal influenza virus vaccine. Use of prime-boosting is another area of study; it consists of immunizing (or priming) an immunologically naïve individual, followed by subsequent boosting (potentially many years later) with a heterologous vaccine, to induce rapid cross-clade seroprotection [<a href="#rid2">2</a>] .</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avian influenza antigens are poor inducers of immunogenicity in humans [<a href="#rid3">3,4</a>]. Several vaccine doses may be required to induce seroprotection (which is logistically challenging in an emergency situation). The use of adjuvants or live attenuated viruses is beneficial to induce a more robust immune response with a lower quantity of antigen; this is important for expediting the induction of immunity as well as optimizing vaccine supply. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serologic tests for the detection of antibody to avian influenza are not standardized, and results are variable among laboratories; it is difficult to compare results between vaccine studies [<a href="#rid5">5</a>]. Setting an international standard for antibody detection is important for standardization of vaccine immunogenicity and for determining correlates of immune protection needed for vaccine approval [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Highly pathogenic avian influenza (HPAI) viruses may be lethal to chickens, whose eggs are usually used for large-scale vaccine production. Careful attention to biosecurity in chicken facilities is important to minimize the risk of avian influenza virus contamination. Development of alternative vaccine production techniques (described below) has been important to reduce reliance on egg-based vaccine production. </p><p></p><p>Current approaches for influenza vaccine development include [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inactivated egg-grown vaccine (including whole-virion and subvirion vaccine). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvanted vaccines, including subvirion, inactivated whole-virion, and virosome vaccines; adjuvants include oil-in-water emulsions such as MF59 and AS03, <a class="drug drug_general" data-topicid="8499" href="/d/drug information/8499.html" rel="external">aluminum hydroxide</a>, and aluminum phosphate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cell culture-derived inactivated whole-virus vaccine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Live attenuated intranasal virus vaccine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>mRNA vaccines − The rapid rollout of mRNA vaccine technology against SARS-CoV-2 infection has pushed mRNA vaccine platform technology to the forefront of clinical development. mRNA vaccines deliver transcripts encoding viral proteins to cells that synthesize and express these proteins, inducing antibody and cellular responses [<a href="#rid8">8-10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenovirus-based influenza vaccines – Adenovirus-based vaccines, which were developed and used to prevent SARS-CoV-2 infections, are also being investigated for the prevention of influenza [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plant-based recombinant influenza vaccines [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H535240691"><span class="h2">Avian influenza H5N1</span></p><p class="headingAnchor" id="H7"><span class="h3">Nonadjuvanted vaccine</span><span class="headingEndMark"> — </span>The United States National Stockpile includes a nonadjuvanted subvirion <a class="drug drug_general" data-topicid="8922" href="/d/drug information/8922.html" rel="external">H5N1 avian influenza vaccine</a> (Sanofi 2007) (<a class="graphic graphic_table graphicRef141146" href="/d/graphic/141146.html" rel="external">table 1</a>). The vaccine is intended for use in adults 18 to 65 years of age and is given as two doses one month apart. </p><p>The safety and efficacy were evaluated in a randomized trial including 451 healthy adults [<a href="#rid13">13</a>]. Participants received two doses of vaccine (containing 90, 45, 15, or 7.5 mcg of hemagglutinin [HA] antigen or placebo). Immunogenicity was poor; the only group in which more than half of subjects reached the predefined immunogenicity threshold was the group that received 90 mcg (a total dose nearly 12 times that of seasonal influenza vaccines) [<a href="#rid14">14</a>]. The vaccine was well tolerated; the most common side effects were pain at the injection site, headache, malaise, and muscle pain.</p><p>In a follow-up study, 337 participants received a third vaccine dose (containing 90, 45, 15, or 7.5 mcg of HA antigen). One month later, microneutralization geometric mean titers were ≥1:40 in 78, 67, 43, and 31 percent of recipients in each group, respectively [<a href="#rid15">15</a>]. Five months later, microneutralization geometric mean titers remained significantly greater than titers after the second dose; these findings suggest that after priming with vaccine, antibody responses can be further enhanced by vaccine boosting.</p><p class="headingAnchor" id="H8"><span class="h3">Adjuvanted vaccines</span><span class="headingEndMark"> — </span>Adjuvants facilitate administration of lower doses of antigen; in addition, they have potential to increase vaccine production capacity [<a href="#rid16">16,17</a>]. Oil-in-emulsion adjuvanted vaccines (AS03 and MF59), but not alum-adjuvanted vaccines, are associated with better overall immune responses [<a href="#rid18">18-23</a>] and have been authorized for use as prepandemic vaccines.</p><p>Some of these "antigen-sparing" approaches have used subvirion or whole-virion vaccine design.</p><p class="headingAnchor" id="H9"><span class="h4">Subvirion vaccines</span></p><p class="headingAnchor" id="H2720012570"><span class="h5">AS03</span><span class="headingEndMark"> — </span>An AS03-adjuvanted recombinant H5N1 split-virion vaccine has been authorized as a prepandemic vaccine for use in the United States (2013) and Europe (2009) (<a class="graphic graphic_table graphicRef141146" href="/d/graphic/141146.html" rel="external">table 1</a>). These vaccines are immunogenic against the homologous vaccine strain and also induce cross-clade neutralizing antibodies against antigenically distinct H5N1 viruses [<a href="#rid20">20,24-26</a>]. </p><p>The safety and efficacy of this vaccine formulation were evaluated in a randomized trial including 400 healthy adults 18 to 60 years of age [<a href="#rid20">20</a>]. Participants received two doses of vaccine 21 days apart; four antigen doses (3.8, 7.5, 15, and 30 mcg HA, with or without AS03) were administered. Among participants who received adjuvanted vaccine, all doses ≥7.5 mcg induced adequate seroprotection after the first vaccine dose; all doses (including the lowest dose of 3.8 mcg) induced adequate seroprotection after the second vaccine dose. The nonadjuvanted vaccines were poorly immunogenic. </p><p>In another study, a two-dose regimen of an even lower dose (1.9 mcg) of AS03 adjuvanted H5N1 vaccine was more immunogenic (92 percent had a fourfold increase in microneutralization titers versus 42 percent) and induced a higher proportion of cross-neutralizing antibodies (39 to 65 percent versus 7 percent) compared with 7.5 mcg of nonadjuvanted vaccine [<a href="#rid24">24</a>]. In subsequent studies enrolling individuals &gt;61 years of age, a two-dose series of 3.75 and 7.5 mcg of AS03-adjuvanted vaccine given 21 days apart induced adequate seroprotection [<a href="#rid25">25,26</a>].</p><p>In a subsequent trial including more than 300 adults age 18 to 64 years, participants were randomly assigned to receive an AS03 subvirion vaccine containing 3.75 mcg of the HA antigen 21 days apart, 14 days apart, 7 days apart, or on the same day [<a href="#rid27">27</a>]. Each of the accelerated schedules met predetermined immunogenicity licensing criteria.</p><p>The most common adverse effect of AS03-adjuvanted vaccine is injection site pain; other adverse effects include myalgia, headache, fatigue, and injection site redness and swelling.</p><p class="headingAnchor" id="H3168960087"><span class="h5">MF59</span><span class="headingEndMark"> — </span>An MF59-adjuvanted H5N1 vaccine has been authorized as a prepandemic vaccine for use in the United States (Audenz 2020) and Europe (Aflunov 2010, Foclivia 2011) (<a class="graphic graphic_table graphicRef141146" href="/d/graphic/141146.html" rel="external">table 1</a>).</p><p>The efficacy of this formulation was evaluated in a trial including 394 healthy adults who were randomly assigned to receive placebo, vaccine alone (45, 30, or 15 mcg per dose), vaccine adjuvanted with MF59 (15 or 7.5 mcg per dose), or vaccine adjuvanted with <a class="drug drug_general" data-topicid="8499" href="/d/drug information/8499.html" rel="external">aluminum hydroxide</a> (30, 15, or 7.5 mcg) [<a href="#rid21">21</a>]. One month after the second vaccine dose, seroprotection was observed more frequently among those who received the MF59-adjuvanted (15 mcg dose) vaccine than the nonadjuvanted (45 mcg dose) vaccine (63 versus 29 percent). </p><p>Other trial data evaluating MF59-adjuvanted H5N1 vaccine suggest that prepandemic priming could be incorporated into seasonal influenza immunization schedules [<a href="#rid28">28-30</a>].</p><p class="headingAnchor" id="H10"><span class="h4">Whole-virion vaccines</span><span class="headingEndMark"> — </span>A Vero cell-derived whole-virion vaccine was authorized as a prepandemic vaccine for use in Europe (Baxter 2009) (<a class="graphic graphic_table graphicRef141146" href="/d/graphic/141146.html" rel="external">table 1</a>).</p><p>The immunogenicity of this formulation was evaluated in phase I and II randomized trials among 275 volunteers who received two doses of vaccine 21 days apart (containing 3.75 mcg, 7.5 mcg, 15 mcg, or 30 mcg of HA antigen with alum-adjuvant or 7.5 or 15 mcg of HA antigen without adjuvant) [<a href="#rid31">31</a>]. The vaccine induced neutralizing antibodies against the clade 1 virus strain used in the vaccine as well as cross-reactive antibodies against clade 2 and 3 strains; the most favorable responses were observed with 7.5 or 15 mcg of HA antigen without adjuvant. </p><p>In a follow-up study, a subset of the individuals received a booster containing 7.5 mcg of HA antigen without adjuvant from an antigenically distinct clade 2.1 strain, 12 to 17 months after the priming regimen [<a href="#rid32">32</a>]. The prime-boost regimen resulted in higher cross-reacting antibody responses against clades 1, 2.1, 2.2, and 2.3 viruses than those induced after the priming regimen. </p><p>Alternative whole virus vaccine candidates have proved immunogenic in several studies [<a href="#rid31">31-36</a>].</p><p class="headingAnchor" id="H3266254734"><span class="h3">Live attenuated intranasal vaccine</span><span class="headingEndMark"> — </span>Live attenuated influenza vaccines containing HA and neuraminidase genes from seasonal influenza viruses are already licensed in the United States. In a pandemic situation, this vaccine formulation would be advantageous due to its high growth yield in eggs and the induction of mucosal immunity that is cross-reactive to antigenically distinct strains.</p><p>Two candidate live attenuated H5N1 vaccines were found to be restricted in replication and only modestly immunogenic after two doses among 59 healthy adults [<a href="#rid37">37</a>]. In a follow-up study five years later, a single dose of nonadjuvanted subunit influenza H5N1 vaccine was administered to individuals primed by live attenuated H5N1 vaccine as well as naïve individuals; greater antibody response was observed among the primed individuals, indicating live attenuated vaccine had induced long-lasting B cell memory [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H1026301831"><span class="h2">Avian influenza H7N9</span><span class="headingEndMark"> — </span>There is no influenza A/H7N9 vaccine currently available for human use. A number of A/H7N9 vaccine candidates have been evaluated; these include:</p><p class="bulletIndent1"><span class="glyph">●</span>A/Anhui/1/2013 H7N9 vaccine [<a href="#rid39">39,40</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>A/Shanghai/2/2013 H7N9 vaccine [<a href="#rid40">40-42</a>]</p><p></p><p class="headingAnchor" id="H18"><span class="h1">PANDEMIC PREPAREDNESS</span><span class="headingEndMark"> — </span>Factors likely to delay widespread availability of pandemic-specific vaccine include production capacity, distribution logistics, and two-dose administration schedules. Additional challenges include limitations in adjuvant availability as well as secondary manufacturing issues such as syringe filling and vaccine formulation. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stockpiling</strong> – Advance vaccine production and stockpiling of antigen and adjuvants may be beneficial to reduce limitations associated with vaccine availability. Some governments (including that of the United States) have stockpiled H5N1 vaccine and liquid adjuvant formulations as part of preparedness planning. However, antigenic diversity of circulating H5N1 viruses may mean that any vaccine prepared in advance may not be well matched to the eventual outbreak strain. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shelf life of stored antigen</strong> – The shelf life of stored bulk antigen is uncertain; one study of AS03A-adjuvanted H5N1 vaccine formulated with bulk antigen that had been stored for four years found that immune responses were similar to those elicited by newly manufactured vaccine [<a href="#rid43">43</a>]. </p><p></p><p class="bulletIndent1">In one randomized trial, influenza H5N1 antigen was administered with and without MF59 adjuvant using material from the United States National Pre-Pandemic Influenza Vaccine Stockpile [<a href="#rid44">44</a>]. At the time of immunization, the oldest stockpiled influenza H5N1 antigen was 12 years old, and the oldest stockpiled MF59 adjuvant was 7 years old. The tolerability and immunogenicity were comparable with historic clinical trial data, despite the extended storage years of antigen or adjuvant. </p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Authorized vaccines</strong> – Pandemic-specific vaccines are developed once a pandemic has been declared and the culprit virus has been characterized. To reduce delay, prepandemic vaccines are developed and authorized for use (but not marketed) prior to declaration of a pandemic. Prepandemic vaccines authorized for human use are summarized in the table (<a class="graphic graphic_table graphicRef141146" href="/d/graphic/141146.html" rel="external">table 1</a>). (See <a class="local">'Authorized vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenges to vaccine development</strong> – There are a number of challenges to development of avian influenza vaccines. Genetic evolution (with several antigenically diverse virus clades and subclades) poses difficulty in selecting the best viruses from which to prepare vaccines. In addition, avian influenza antigens are poor inducers of immunogenicity in humans, and serologic tests for detection of antibody to avian influenza are not standardized. (See <a class="local">'Challenges and novel approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Novel approaches</strong> – Highly pathogenic avian influenza (HPAI) viruses may be lethal to chickens,<strong> </strong>whose eggs are used for large-scale vaccine production. Novel approaches include adjuvanted vaccines, cell culture-derived vaccines, live attenuated intranasal vaccines, and mRNA vaccines. (See <a class="local">'Challenges and novel approaches'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stockpiling</strong> – Advance vaccine production and stockpiling of antigen and adjuvants may be beneficial to reduce limitations associated with vaccine availability. (See <a class="local">'Pandemic preparedness'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Vaccines for pandemic influenza. Human regulatory, European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/pandemic-influenza/vaccines-pandemic-influenza (Accessed on March 21, 2023).</li><li><a class="nounderline abstract_t">Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631.</a></li><li><a class="nounderline abstract_t">Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687.</a></li><li><a class="nounderline abstract_t">Stephenson I, Nicholson KG, Glück R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959.</a></li><li><a class="nounderline abstract_t">Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:4056.</a></li><li><a class="nounderline abstract_t">Stephenson I, Heath A, Major D, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009; 15:1252.</a></li><li><a class="nounderline abstract_t">Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458.</a></li><li><a class="nounderline abstract_t">Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther 2017; 25:1316.</a></li><li><a class="nounderline abstract_t">Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 2019; 37:3326.</a></li><li><a class="nounderline abstract_t">Rcheulishvili N, Papukashvili D, Liu C, et al. Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs- focus on the bigger picture. Front Immunol 2022; 13:1025884.</a></li><li><a class="nounderline abstract_t">Kerstetter LJ, Buckley S, Bliss CM, Coughlan L. Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Front Immunol 2020; 11:607333.</a></li><li><a class="nounderline abstract_t">Shoji Y, Chichester JA, Jones M, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 2011; 7 Suppl:41.</a></li><li><a class="nounderline abstract_t">Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343.</a></li><li><a class="nounderline abstract_t">Poland GA. Vaccines against avian influenza--a race against time. N Engl J Med 2006; 354:1411.</a></li><li><a class="nounderline abstract_t">Zangwill KM, Treanor JJ, Campbell JD, et al. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197:580.</a></li><li><a class="nounderline abstract_t">Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210.</a></li><li><a class="nounderline abstract_t">Hehme N, Engelmann H, Künzel W, et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002; 191:203.</a></li><li><a class="nounderline abstract_t">Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937.</a></li><li><a class="nounderline abstract_t">Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657.</a></li><li><a class="nounderline abstract_t">Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580.</a></li><li><a class="nounderline abstract_t">Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667.</a></li><li><a class="nounderline abstract_t">Keitel WA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008; 198:1309.</a></li><li><a class="nounderline abstract_t">Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644.</a></li><li><a class="nounderline abstract_t">Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642.</a></li><li><a class="nounderline abstract_t">Heijmans S, De Meulemeester M, Reynders P, et al. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054.</a></li><li><a class="nounderline abstract_t">Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729.</a></li><li><a class="nounderline abstract_t">Lasko B, Reich D, Madan A, et al. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 2011; 204:574.</a></li><li><a class="nounderline abstract_t">Belshe RB, Frey SE, Graham IL, et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1420.</a></li><li><a class="nounderline abstract_t">Lopez P, Caicedo Y, Sierra A, et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J Infect Dis 2011; 203:1719.</a></li><li><a class="nounderline abstract_t">Herbinger KH, von Sonnenburg F, Nothdurft HD, et al. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults. Hum Vaccin Immunother 2014; 10:92.</a></li><li><a class="nounderline abstract_t">Ehrlich HJ, Müller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573.</a></li><li><a class="nounderline abstract_t">Ehrlich HJ, Müller M, Fritsch S, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113.</a></li><li><a class="nounderline abstract_t">Kreijtz JH, Goeijenbier M, Moesker FM, et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014; 14:1196.</a></li><li><a class="nounderline abstract_t">de Vries RD, Altenburg AF, Nieuwkoop NJ, et al. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial. J Infect Dis 2018; 218:614.</a></li><li><a class="nounderline abstract_t">Cheng A, Hsieh SM, Pan SC, et al. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial. J Microbiol Immunol Infect 2019; 52:685.</a></li><li><a class="nounderline abstract_t">Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009; 48:1087.</a></li><li><a class="nounderline abstract_t">Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953.</a></li><li><a class="nounderline abstract_t">Talaat KR, Luke CJ, Khurana S, et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014; 209:1860.</a></li><li><a class="nounderline abstract_t">Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369:2564.</a></li><li><a class="nounderline abstract_t">Rudenko L, Isakova-Sivak I, Naykhin A, et al. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis 2016; 16:303.</a></li><li><a class="nounderline abstract_t">Mulligan MJ, Bernstein DI, Winokur P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014; 312:1409.</a></li><li><a class="nounderline abstract_t">Madan A, Segall N, Ferguson M, et al. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults. J Infect Dis 2016; 214:1717.</a></li><li><a class="nounderline abstract_t">Godeaux O, Izurieta P, Madariaga M, et al. Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years. Vaccine 2015; 33:2189.</a></li><li><a class="nounderline abstract_t">Oshansky CM, Zhou J, Gao Y, et al. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). Vaccine 2019; 37:435.</a></li></ol></div><div id="topicVersionRevision">Topic 7000 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/pandemic-influenza/vaccines-pandemic-influenza" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vaccines for pandemic influenza. Human regulatory, European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/pandemic-influenza/vaccines-pandemic-influenza (Accessed on March 21, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843132" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639491" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14683655" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17412461" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751587" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reproducibility of serologic assays for influenza virus A (H5N1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16870521" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Development of vaccines against influenza H5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457665" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31079849" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36325349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs- focus on the bigger picture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33633727" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266846" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571878" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571885" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vaccines against avian influenza--a race against time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18237269" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15776364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12458361" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425416" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714186" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707753" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260764" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808338" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20423222" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18576945" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21450995" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606531" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791660" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25291578" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606530" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24047817" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550874" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19712040" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455987" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912453" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31255574" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281330" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540952" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604819" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24224560" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A recombinant viruslike particle influenza A (H7N9) vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26673391" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25291577" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609809" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25090645" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30553570" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
